Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E
Department of Pathology, Hiroshima University, School of Medicine, Japan.
Biochem Biophys Res Commun. 1992 Nov 30;189(1):227-32. doi: 10.1016/0006-291x(92)91548-5.
Amplification of the c-met gene, that encodes hepatocyte growth factor receptor, was examined on human esophageal, gastric and colorectal carcinomas. Six (55%) of the 11 gastric carcinoma cell lines and 15 (23%) of the 64 advanced gastric carcinomas showed the c-met gene amplification. Among them, c-met amplification was detected in 5 gastric cancer cell lines, derived from scirrhous gastric carcinoma and in 5 (38%) of 13 scirrhous gastric carcinoma tissues. Furthermore, patients of gastric carcinoma with c-met amplification showed significantly advanced tumor stage and poorer prognosis than those without the amplification. Conversely, no amplification was detected in any of the esophageal and colorectal carcinoma cell lines as well as carcinoma tissues except one colonic carcinoma. These results overall suggest that amplification of the c-met gene might participate in carcinogenesis and progression of stomach cancer, especially scirrhous type stomach carcinoma.
对编码肝细胞生长因子受体的c-met基因在人食管癌、胃癌和结直肠癌中的扩增情况进行了检测。11种胃癌细胞系中有6种（55%），64例进展期胃癌中有15例（23%）显示出c-met基因扩增。其中，在5种源自硬癌型胃癌的胃癌细胞系以及13例硬癌型胃癌组织中的5例（38%）中检测到了c-met扩增。此外，与未发生扩增的患者相比，发生c-met扩增的胃癌患者肿瘤分期明显更晚，预后更差。相反，除1例结肠癌外，在任何食管癌细胞系、结肠癌细胞系以及癌组织中均未检测到扩增。这些结果总体表明，c-met基因扩增可能参与胃癌尤其是硬癌型胃癌的发生和进展。
